AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7657418
Drug: Albuterol (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (360 micrograms total, 90 micrograms per dose, 4 metered doses)
Trial: 31375606
Drug: Levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5 mg/kg alternate day
Trial: 25350782
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (50,000 IU of cholecalciferol weekly for 8 weeks)
Trial: 15566933
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg every 8 hours for </=3 doses
Trial: 15566933
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg every 8 hours for </=3 doses
Trial: 12089976
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of scaling and metronidazole gel
Trial: 9066835
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray (220 micrograms/day)
Trial: 9066835
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray (110 micrograms/day, dose reduction allowed)
Trial: 14669818
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field in combination with essential oils administered for 26 weeks
Trial: 1359666
Drug: Non-sedative antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-sedative antihistamine
Trial: 25846070
Drug: Montelukast treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast treatment for 9 months
Trial: 25846070
Drug: Routine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine and placebo treatment
Trial: 19531445
Drug: Accelerated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated treatment (omitting three cycles of FSH/IUI)
Trial: 19531445
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (three cycles of CC/IUI, three cycles of FSH/IUI, up to six cycles of IVF)
Trial: 19165198
Drug: Accelerated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated treatment
Trial: 18284641
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated SGA controls)
Trial: 11862171
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg/d for 12 weeks)
Trial: 10550134
Drug: 24-hour paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24-hour paclitaxel infusion
Trial: 2314151
Drug: Nalmefene (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (1 mg intravenous)
Trial: 7401832
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% lidocaine applied to the carotid bifurcation (12 patients)
Trial: 31693275
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg
Trial: 31693275
Drug: Intravenous exendin
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous exendin (9-39) 600 pmol/kg/min
Trial: 15473615
Drug: Higher-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose remifentanil (0.5 microg kg(‐1)min(‐1))
Trial: 15473615
Drug: Lower-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose remifentanil (0.25 microg kg(‐1)min(‐1))
Trial: 15473615
Drug: Higher-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose remifentanil
Trial: 11479476
Drug: Tezosentan (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (5, 20, 50, and 100 mg over 1 hour each)
Trial: 14688860
Drug: Rhesus‐human reassortant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus‐human reassortant rotavirus (RRV‐TV) vaccine
Trial: 14688860
Drug: Monthly rates
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly rates of rotavirus-related episodes
Trial: 27497519
Drug: Salmon intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon intake (two 150-g portions per week)
Trial: 23790990
Drug: State-sponsored program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-sponsored program with twice-weekly gym classes
Trial: 11355917
Drug: Primary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary prevention by dietary intervention and drugs; specific details not mentioned.
Trial: 3061425
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (mean dose 11.5 mg over 3.4 min)
Trial: 3061425
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (mean dose 6.0 mg over 3.3 min)
Trial: 25605544
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human erythropoietin (rhEPO) 33,000 IU administered at days 1-3
Trial: 25605544
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 1,000 mg per day for 3 days + 0.9% normal saline (placebo)
Trial: 12452944
Drug: High-dose interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha therapy (daily 9 MU for 4 weeks, then 6 MU for weeks 5-8, 3 MU for weeks 9-12, and 1.5 MU for weeks 13-48) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Trial: 12452944
Drug: Standard-dosage interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dosage interferon-alpha therapy (thrice weekly 6 MU for 12 weeks, then 3 MU for 36 weeks) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Trial: 9605002
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg intravenously, 5 minutes before chemotherapy)
Trial: 9605002
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg intravenously, 5 minutes before chemotherapy) with additional doses if vomiting occurs
Trial: 8583516
Drug: Enhanced Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Care day treatment program including drug free contingent work therapy and housing
Trial: 2666339
Drug: RHEZ6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHEZ6 regimen (4 drug, 6 months: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide)
Trial: 2666339
Drug: RHE9 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHE9 regimen (3 drug, 9 months: Rifampicin, Isoniazid, Ethambutol)
Trial: 140084
Drug: bufexamac cream
RxNorm normalized name: bufexamac
DrugBank: Bufexamac (DB13346)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bufexamac cream
Trial: 25654175
Drug: Active quality
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active quality improvement interventions (nurse specialist, monthly audit-feedback, network educational events, internet blog)
Trial: 22480093
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg thrice daily
Trial: 19523083
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test in obese children and adolescents
Trial: 16733916
Drug: estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol valerate (E2 V) 1 mg/d + medroxyprogesterone acetate (MPA) 2 mg/d
Trial: 16733916
Drug: conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conjugated equine estrogen 0.45 mg/d + MPA 2 mg/d
Trial: 16733916
Drug: tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 1.25 mg/d
Trial: 9150774
Drug: Adenosine infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine infusion, 80 micrograms.kg-1.min-1 during surgery and 40 micrograms.kg-1.min-1 for 3 hours postoperatively
Trial: 9150774
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during surgery
Trial: 29889390
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with proton pump inhibitors (PPIs)
Trial: 29889390
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with PPI + ursodeoxycholic acid (UDCA)
Trial: 24867408
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g bLF daily for 1 year
Trial: 24867408
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g bLF daily for 1 year
Trial: 24867408
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g bLF daily for 1 year
Trial: 20138189
Drug: GM-CSF (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (150 microg) + hepatitis B vaccine (20 microg)
Trial: 20138189
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (40 microg) only
Trial: 20138189
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (20 microg) each time
Trial: 19457618
Drug: Oxytocin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (single dose administered intranasally)
Trial: 19457618
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single dose administered intranasally)
Trial: 16794364
Drug: lanreotide 30
RxNorm normalized name: lanreotide 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide 30 mg
Trial: 10845898
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT)
Trial: 29887289
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous Oxide (N2O) inhalation (50% for 30 minutes)
Trial: 24836523
Drug: Organ-specific dose
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organ-specific dose reduction (OSDR) and attenuation-based tube potential selection (ATPS)
Trial: 20195613
Drug: Modeling in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeling in value-based medicine (VBM)
Trial: 19173919
Drug: rh-endostatin plus
RxNorm normalized name: Endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-endostatin plus NP chemotherapy
Trial: 12051882
Drug: Mitomycin 8
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin 8 mg/m², Doxorubicin 40 mg/m², Cisplatin 60 mg/m² (MAP chemotherapy)
Trial: 10063926
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 infusion (30 microg/hr)
Trial: 23851069
Drug: Dapagliflozin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin at doses of 0.3mg and above
Trial: 23851069
Drug: Dapagliflozin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin at doses of 0.1mg and above
Trial: 21415052
Drug: initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial combination therapy
Trial: 21415052
Drug: initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial combination with prednisone
Trial: 21415052
Drug: initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial combination with infliximab
Trial: 19105889
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg vitamin D(2)
Trial: 17339864
Drug: dl-Methylphenidate (MPH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min before ethanol (0.6 gm/kg)
Trial: 17339864
Drug: dl-Methylphenidate (MPH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min after ethanol (0.6 gm/kg)
Trial: 10967897
Drug: nCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP treatment (Group L)
Trial: 9366458
Drug: Sufentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (3 microg/kg) administered over 2 min
Trial: 9366458
Drug: Muscle relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle relaxant (Pancuronium 0.1 mg/kg) administered after sufentanil
Trial: 3460327
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VP16‐213 with cytosine arabinoside and doxorubicin) (group 2: n = 10)
Trial: 25586270
Drug: Restrictive RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive RBC transfusion (Hb < 9.7 g/dL; < 6 mmol/L)
Trial: 25586270
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion (Hb < 11.3 g/dL; < 7 mmol/L)
Trial: 19372341
Drug: Colloid preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid preload (15 mL/kg hydroxyethyl starch (HES) 130/0.4 [Voluven 6%])
Trial: 16583194
Drug: PEG-C preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-C preparation (polyethylene glycol solution plus contrast medium)
Trial: 16583194
Drug: PEG preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG preparation (polyethylene glycol solution)
Trial: 11489000
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) and Carboplatin (AUC 5)
Trial: 11489000
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2 in 3 h) and Carboplatin (AUC 5)
Trial: 8041980
Drug: Clonidine 0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.005 mg/kg p.o.
Trial: 8041980
Drug: Lorazepam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 0.03 mg/kg p.o.
Trial: 2656310
Drug: Gestrinone 2.5
RxNorm normalized name: gestrinone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 2.5 mg capsules three times weekly orally
Trial: 2656310
Drug: Gestrinone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 5.0 mg capsules twice weekly orally
Trial: 2656310
Drug: Gestrinone 5
RxNorm normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 5 mg vaginal tablets three times weekly
Trial: 2656310
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment for 24 months
Trial: 2656310
Drug: Discontinuation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation at 1 year
Trial: 16732083
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl (50 microg/kg)
Trial: 16732083
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl (10 microg/kg)
Trial: 15623588
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (TXT q 3w)
Trial: 15623588
Drug: Docetaxel 30
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 30 mg/m2 days 1, 8, 15, 22, and 29 every 6 weeks + prednisone 5 mg twice a day for a total of 5 cycles (TXT qw)
Trial: 15623588
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (MTZ q 3w)
Trial: 11717659
Drug: Presumptive sexually
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumptive sexually transmitted disease treatment during pregnancy
Trial: 9158077
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (Premarin 0.625 mg and Norgestrel 1 mg) for more than 1 year
Trial: 8198022
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg/day plus bezafibrate 400 mg/day
Trial: 8198022
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/day plus bezafibrate 400 mg/day
Trial: 8198022
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/day plus cholestyramine 8 g/day
Trial: 3294021
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg daily
Trial: 3294021
Drug: Verapamil 160
RxNorm normalized name: verapamil 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 160 mg twice daily + Bendrofluazide 5 mg daily
Trial: 3294021
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg daily + Verapamil 160 mg twice daily
Trial: 31719072
Drug: Cannabis-based medicine
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration, treated for 6 months.
Trial: 31719072
Drug: Cannabis-based medicine
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis-based medicine extract (CBME)
Trial: 12598435
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and prophylactic treatment (measurement of anterior chamber depth and intraocular pressure, followed by laser iridotomy for those with occludable angles)
Trial: 7552933
Drug: Loratadine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine, 20 mg once daily for 4 weeks
Trial: 1664832
Drug: Temafloxacin 600
RxNorm normalized name: temafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 600 mg once daily
Trial: 7194172
Drug: Triphasic formulation
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic formulation (ethinyl oestradiol and levonorgestrel)
Trial: 23130817
Drug: Vitamin BC
RxNorm normalized name: Vitamin Bc
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin BC capsules plus corresponding deficient hematinics (for groups I, II, III, IV)
Trial: 23130817
Drug: Vitamin BC
RxNorm normalized name: Vitamin Bc
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin BC capsules only (for group V)
Trial: 15569851
Drug: NT-proBNP >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP > 50 pmol/L and CRP > 0.84 mg/L
Trial: 10369709
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (20 g free glutamine replacing 3.8 g of total nitrogen)
Trial: 8763084
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine injected into the buttock or internal aspect of the thigh
Trial: 8763084
Drug: Inactivated whole-virus
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole-virus vaccine
Trial: 1868502
Drug: Captopril (37.5-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (37.5-75 mg/day)
Trial: 1868502
Drug: Ibopamine (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (150-300 mg/day)
Trial: 28975718
Drug: Febuxostat 40
RxNorm normalized name: febuxostat 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 40 mg (increased to 80 mg if serum UA level was ≥6.0 mg/dl on day 14)
Trial: 19221871
Drug: Community-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based treatment (COMM)